Исследование влияния полиморфизма генов CYP3A5, CYP2B6 и NAT2 на эффективность лечения туберкулёза с множественной лекарственной устойчивостью

1. Vaniev EV, Vasilieva IA, Ergeshov AE, Bagdasaryan TR. Difficulties in managing the patient with multiple drug resistant tuberculosis and concurrent conditions. Tuberculosis and Lung Diseases. 2016;94(7):56-60. (In Russ). DOI: 10.21292/2075-1230-2016-94-7-56-60.

2. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138(1):103–41. DOI: 10.1016/j.pharmthera.2012.12.007.

3. Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metabolism Reviews. 2009;41(2):289-295. DOI: 10.1080/03602530902843483.

4. Mozhokina GN, Kazakov AV, Elistratova NA, Popov SA. Biotransformation enzymes for xenobiotics and personalization of treatment regimens for tuberculosis patients. Tuberculosis and Lung Diseases. 2016;94(4):6-12. (In Russ). DOI: 10.21292/2075-1230-2016-94-4-6-12.